The Use of Nirmatrelvir-ritonavir in a Case of Breakthrough Long COVID

Linda N. Geng, H. Bonilla, R. Shafer, M. Miglis, Phillip C. Yang
{"title":"The Use of Nirmatrelvir-ritonavir in a Case of Breakthrough Long COVID","authors":"Linda N. Geng, H. Bonilla, R. Shafer, M. Miglis, Phillip C. Yang","doi":"10.14218/erhm.2022.00045","DOIUrl":null,"url":null,"abstract":"Post-acute sequelae of SARS-CoV-2 (PASC) or long COVID is a major public health problem. The underlying mechanism(s) of this disease remains unclear, and there is a lack of effective therapies. We report a case of a 47-year-old patient who experienced breakthrough acute COVID-19 with PASC after two doses of COVID-19 vaccination, and its symptom resolution following a course of the novel combination of antiviral nirmatrelvir-ritonavir. One of several leading hypotheses on the pathogenesis of PASC is a persistent viral reservoir. This case report raises important questions on the potential role of antiviral therapies in long COVID, and the need for further research and clinical trials in this field of study.","PeriodicalId":12074,"journal":{"name":"Exploratory Research and Hypothesis in Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exploratory Research and Hypothesis in Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14218/erhm.2022.00045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Post-acute sequelae of SARS-CoV-2 (PASC) or long COVID is a major public health problem. The underlying mechanism(s) of this disease remains unclear, and there is a lack of effective therapies. We report a case of a 47-year-old patient who experienced breakthrough acute COVID-19 with PASC after two doses of COVID-19 vaccination, and its symptom resolution following a course of the novel combination of antiviral nirmatrelvir-ritonavir. One of several leading hypotheses on the pathogenesis of PASC is a persistent viral reservoir. This case report raises important questions on the potential role of antiviral therapies in long COVID, and the need for further research and clinical trials in this field of study.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Nirmatrelvir-ritonavir在突破长期COVID病例中的应用
SARS-CoV-2急性后后遗症(PASC)或长冠状病毒是一个重大的公共卫生问题。这种疾病的潜在机制尚不清楚,也缺乏有效的治疗方法。我们报告了一例47岁的患者,在两剂COVID-19疫苗接种后出现突破性急性COVID-19合并PASC,并在抗病毒药物nirmatrelvir-ritonavir的新型组合疗程后症状消退。关于PASC发病机制的几个主要假设之一是持久性病毒库。该病例报告提出了抗病毒治疗在长期COVID中的潜在作用的重要问题,以及在该研究领域进一步研究和临床试验的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Vaccine Adjuvants: From Empirical to a More Rational Drug Design Feasibility and Advantages of Designing Proteolysis Targeting Chimeras Targeting Peroxisome Proliferator-activated Receptors for Cancer Treatment Placental Malaria and Its Relationship with Neonatal Birth Weight among Primigravidae: An Analytical Cross-sectional Study. Immunotherapy in Colorectal Cancer: A Review Challenges and Opportunities Associated with Lifting the Zero COVID-19 Policy in China.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1